Compare BVFL & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BVFL | NNNN |
|---|---|---|
| Founded | 1873 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.8M | 154.1M |
| IPO Year | 2023 | 2023 |
| Metric | BVFL | NNNN |
|---|---|---|
| Price | $21.38 | $3.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.4K | ★ 44.3K |
| Earning Date | 10-23-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.19 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $38.65 | $446.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.37 | $3.09 |
| 52 Week High | $22.70 | $44.73 |
| Indicator | BVFL | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 44.07 | 47.12 |
| Support Level | $20.36 | $3.21 |
| Resistance Level | $21.86 | $4.43 |
| Average True Range (ATR) | 0.48 | 0.35 |
| MACD | -0.11 | 0.13 |
| Stochastic Oscillator | 16.78 | 58.45 |
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. It operates in one segment commercial banking. The company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).